Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Christoph, Aderhold"'
Autor:
LENA HUBER, RICHARD BIRK, MANUEL KNUETTEL, NICOLE ROTTER, CHRISTOPH ADERHOLD, CLAUDIA SCHERL, ANNE LAMMERT, FREDERIC JUNGBAUER, BENEDIKT KRAMER
Publikováno v:
Anticancer research. 42(7)
The rise of targeted therapies in the treatment of head and neck squamous cell carcinoma (HNSCC) has considerably widened the treatment range. Matrix metalloproteinases (MMPs) are key regulators of the tumor development of many cancer entities, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16ba2f15f5a8c3bb04caedb486705717
https://pubmed.ncbi.nlm.nih.gov/35790279
https://pubmed.ncbi.nlm.nih.gov/35790279
Autor:
Cornelia Emika Mueller, Benedikt Kramer, Anne Lammert, J. Ulrich Sommer, Richard Birk, Stephan Hoch, Angela Schell, Claudia Scherl, Nicole Rotter, Lena Huber, Christoph Aderhold
Publikováno v:
Anticancer Research. 40:6195-6203
Background Head and neck squamous cell cancer (HNSCC) affects the oral cavity and the pharynx. The aim of the study was to investigate the effects of selective tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib, nilotinib and dasatinib and the ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7679ab1e641d23b0ef43a5cb20ad924
https://doi.org/10.21873/anticanres.14639
https://doi.org/10.21873/anticanres.14639
Autor:
Angela Schell, Lena Huber, Bendikt Kramer, Nicole Rotter, Christoph Aderhold, C Emika Mueller, Richard Birk
Publikováno v:
Anticancer Research. 40:3847-3855
Background/aim The effects of tyrosine kinase inhibitors (TKI) in head and neck squamous cell cancer (HNSCC) are not fully understood. We investigated the effects of selective TKIs erlotinib, gefitinib, nilotinib, and dasatinib and the mTOR-inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df32efe67c84461b9a98f3257b90df38
https://doi.org/10.21873/anticanres.14374
https://doi.org/10.21873/anticanres.14374
Publikováno v:
Molecular and Clinical Oncology
Patients with head and neck squamous cell carcinoma (HNSCC) are at risk for local and regional relapse, as well as for occurrence of synchronous or metachronous secondary carcinoma. The aim of this retrospective study was to evaluate the frequency of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8862ef50f65469d04b5b36995b361ff2
http://europepmc.org/articles/PMC7087480
http://europepmc.org/articles/PMC7087480
Publikováno v:
Cureus
The secondary manifestation of a marginal zone lymphoma (MZL), which is a less common type of B-cell non-Hodgkin's Lymphoma (NHL), in the larynx is a rarity. We report a case of the secondary involvement of the larynx following MZL in a 72-year-old w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff70f99e90d731cf33384ca57dada658
http://europepmc.org/articles/PMC7980312
http://europepmc.org/articles/PMC7980312
Autor:
Nicole Rotter, Roland Hülse, Boris A. Stuck, Karl Hörmann, Angela Schell, Christoph Aderhold, Julia Nguyen
Publikováno v:
Ear, nose,throat journal. 101(6)
Introduction: While the cochleotoxicity of cisplatin has been well investigated, less is known about the effects of platinum-based chemotherapy on the vestibular system. In particular, there is a lack of prospective studies using modern laboratory ve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f2b65bac1aef792f059c4efe25796cc
https://pubmed.ncbi.nlm.nih.gov/32921181
https://pubmed.ncbi.nlm.nih.gov/32921181
Autor:
Claudia Scherl, Frederic Jungbauer, Nicole Rotter, Richard Birk, Anne Lammert, Lena Huber, Manuel Knuettel, Christoph Aderhold, Benedikt Kramer
Publikováno v:
Anticancer research. 40(10)
BACKGROUND Targeted therapies in the treatment of head and neck squamous cell carcinoma (HNSCC) are subject to extensive research. Different mutations of genes belonging to the fibroblast growth factor (FGF) family have been detected in HNSCC. In thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b31e1325a557c4759523d10dc21d360
https://pubmed.ncbi.nlm.nih.gov/32988886
https://pubmed.ncbi.nlm.nih.gov/32988886
Autor:
Anne Lammert, Frederic Jungbauer, Christoph Aderhold, Benedikt Kramer, Nicole Rotter, Lena Huber, Richard Birk
Publikováno v:
Anticancer research. 40(2)
BACKGROUND Despite extensive research into new treatment options, the prognosis for head and neck squamous cell carcinoma remains poor. Platelet-derived growth factor (PDGF) is up-regulated in HNSCC and expression levels decrease after surgery, sugge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3c02b23a229c5f24fb3a21aea1aeffb
https://pubmed.ncbi.nlm.nih.gov/32014925
https://pubmed.ncbi.nlm.nih.gov/32014925
Autor:
Christoph Aderhold, Nicole Rotter, Benjamin A. Kansy, Sonja Ludwig, Anne Lammert, Benedikt Kramer, Richard Birk, Stephan Lang, Lena Huber
Publikováno v:
Cancer Genomics Proteomics
Background: We investigated the expression patterns of cluster of differentiation (CD) 44 and amphiregulin (AREG), two signaling molecules essential for cell proliferation and differentiation, under the influence of selective tyrosine kinase inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bd29648fc3da384800a6b3002d82311
https://www.ncbi.nlm.nih.gov/pubmed/32859636
https://www.ncbi.nlm.nih.gov/pubmed/32859636
Autor:
Angela Wenzel, Christoph Aderhold, Klaus Feist, Randolf Riemann, Maja Boerger, Burkard M. Lippert, Renate Petrasch, Benedikt Kramer, Karl Hoermann
Publikováno v:
Nutrition and Cancer. 71:424-437
Disease and therapy of head and neck cancer impair quality of life (QOL). QOL varies profoundly during therapy and follow-up. Aim We sought to monitor QOL and nutritional status of patients before, during and after therapy (AT). Patients and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b5806b97e115b9acdb33932e93d477b
https://doi.org/10.1080/01635581.2018.1506492
https://doi.org/10.1080/01635581.2018.1506492